ALS ‘Urgency’, US FDA Regulatory Environment Justify Filing NurOwn, BrainStorm Says

 
• By Sue Sutter
Steep climb
BrainStorm's ALS drug may face a steep climb to US regulatory approval. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet